Search Results for: 99

March 23, 2026 08:00 ET – Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from FDA and previously from EMA enables company to finalize protocol for pivotal Phase 3 clinical trial while pursuing strategic […]

March 12, 2026 08:00 ET – Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma – – Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales – – Cash and cash equivalents of $13.1 million as of December 31, 2025;

February 18, 2026 08:00 ET – Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales – – Rasayana to assume all responsibility and costs for SYN-020 development and commercialization – ROCKVILLE, Md., Feb. 18,

February 03, 2026 08:00 ET – Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturday, 07 February 2026 – – Preclinical data will highlight synergistic antitumor activity

December 29, 2025 08:00 ET – EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size, repeated dosing of VCN-01, and an adaptive design to potentially optimize trial timelines and outcomes – – Theriva to schedule an End-of-Phase 2